Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as a observational study.

This observational study involved a series of migraine patients affected by either migraine with or without aura, who were investigated for any changes in their frequencies and their migraine aura attack characteristics observed during treatment with anti-CGRP Mabs over a 1-year period.

Who Took Part

Twelve migraine patients were included, seven of whom were treated with erenumab, 2 with fremanezumab, and 3 with galcanezumab.

Clinical data were collected at baseline, which were defined as 3 months prior to the initiation of treatment, and thereafter at each trimester, over the 1-year treatment period.

How the Study Was Run

The parameters included the number of headache and migraine days/month, the frequency of aura episodes, the number of days with acute drug intakes/month, and the scores from the migraine disability status scale (MIDAS), and the Headache Impact Test 6 (HIT-6).

What Was Measured

The subject headings attached to it are Migraine with Aura, Calcitonin Gene-Related Peptide, Migraine Disorders, Headache and Epilepsy.

The authors tagged it with the keywords anti-CGRP monoclonal antibodies, calcitonin gene-related peptide (CGRP), cortical spreading depression and migraine aura.

What This Means in Plain Language

This is a observational study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (CNS neuroscience & therapeutics), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.